AR107494A1 - Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma - Google Patents

Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma

Info

Publication number
AR107494A1
AR107494A1 ARP170100246A ARP170100246A AR107494A1 AR 107494 A1 AR107494 A1 AR 107494A1 AR P170100246 A ARP170100246 A AR P170100246A AR P170100246 A ARP170100246 A AR P170100246A AR 107494 A1 AR107494 A1 AR 107494A1
Authority
AR
Argentina
Prior art keywords
azd9291
salt
aniline
preparation
formula
Prior art date
Application number
ARP170100246A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Telford
Alistair John Boyd
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57984913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR107494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR107494A1 publication Critical patent/AR107494A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP170100246A 2016-02-01 2017-01-31 Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma AR107494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662289390P 2016-02-01 2016-02-01

Publications (1)

Publication Number Publication Date
AR107494A1 true AR107494A1 (es) 2018-05-02

Family

ID=57984913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100246A AR107494A1 (es) 2016-02-01 2017-01-31 Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma

Country Status (18)

Country Link
US (1) US11180477B2 (https=)
EP (1) EP3411038B1 (https=)
JP (1) JP6812449B2 (https=)
KR (1) KR102749892B1 (https=)
CN (1) CN108495632B (https=)
AR (1) AR107494A1 (https=)
AU (1) AU2017214243B2 (https=)
BR (1) BR112018014712B1 (https=)
CA (1) CA3011809C (https=)
CO (1) CO2018007008A2 (https=)
ES (1) ES2834608T3 (https=)
IL (1) IL260665B (https=)
MX (1) MX378363B (https=)
MY (1) MY185367A (https=)
RU (1) RU2733376C2 (https=)
TW (1) TWI745345B (https=)
WO (1) WO2017134051A1 (https=)
ZA (1) ZA201805790B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CN107556293B (zh) * 2017-09-19 2019-12-03 福建省微生物研究所 一种奥西替尼的合成工艺
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
KR20240055046A (ko) 2021-09-02 2024-04-26 신톤 비.브이. 오시머티닙을 제조하는 방법
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070401A (en) * 1972-02-19 1978-01-24 Mitsui Toatsu Chemicals Inc. Method for the preparation of a halogenated aromatic amine
CN103702990B (zh) 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN110526912B (zh) * 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
CN104817541B (zh) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法

Also Published As

Publication number Publication date
ES2834608T3 (es) 2021-06-18
RU2018130327A (ru) 2020-03-04
AU2017214243A1 (en) 2018-09-06
MX378363B (es) 2025-03-10
CN108495632B (zh) 2021-12-31
TWI745345B (zh) 2021-11-11
BR112018014712A2 (pt) 2018-12-11
TW201736364A (zh) 2017-10-16
JP2019508387A (ja) 2019-03-28
WO2017134051A1 (en) 2017-08-10
US20210122734A1 (en) 2021-04-29
MY185367A (en) 2021-05-11
RU2018130327A3 (https=) 2020-03-26
MX2018008966A (es) 2018-09-03
RU2733376C2 (ru) 2020-10-01
CA3011809C (en) 2024-02-27
KR20180101610A (ko) 2018-09-12
US11180477B2 (en) 2021-11-23
BR112018014712B1 (pt) 2023-10-31
IL260665B (en) 2021-08-31
AU2017214243B2 (en) 2019-07-18
JP6812449B2 (ja) 2021-01-13
KR102749892B1 (ko) 2025-01-07
EP3411038B1 (en) 2020-09-09
CN108495632A (zh) 2018-09-04
EP3411038A1 (en) 2018-12-12
ZA201805790B (en) 2024-10-30
CO2018007008A2 (es) 2018-07-19
CA3011809A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
AR107494A1 (es) Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
AR126445A2 (es) Metodo para preparar inhibidores de btk
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
PE20170300A1 (es) Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
AR074845A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
PE20180327A1 (es) Proceso para preparar 4-amino-piridazinas
AR078916A1 (es) Procedimiento para la purificacion de paliperidona
BR112015029714A2 (pt) processo para preparar derivados de 4,6-bis(ariloxi)pirimidina
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
AR080921A1 (es) Proceso para la preparacion de amidas de acido pirazolcarboxilico
MX394430B (es) Proceso para la preparación de 5-fluoro-1h-pirazoles.
AR109248A1 (es) Procedimiento para la preparación de 4-fenilbutirato y sus usos
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
MX2017006298A (es) Proceso para producir acido acetico introduciendo un compuesto de litio.
AR087345A1 (es) Metodos para la preparacion de compuestos de tiofeno
AR066054A1 (es) Proceso para preparar galantamina
MX2018004338A (es) Proceso para sintesis de pirfenidona.
MX383794B (es) Procedimiento para la preparacion de un derivado de furfural.
ES2531069T3 (es) Proceso para la producción de tartrato de L-carnitina
AR102980A1 (es) Un proceso para la fabricación de idalopirdina
AR106195A1 (es) Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis
AR093373A1 (es) Procedimiento de sintesis del (2e)-3-(3,4-dimetoxifenil)prop-2-enonitrilo y aplicacion a la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR089376A1 (es) Proceso para la preparacion de oxido estanico

Legal Events

Date Code Title Description
FG Grant, registration